346 related articles for article (PubMed ID: 15200157)
1. Evaluation of the Xpa-deficient transgenic mouse model for short-term carcinogenicity testing: 9-month studies with haloperidol, reserpine, phenacetin, and D-mannitol.
Lina BA; Woutersen RA; Bruijntjes JP; van Benthem J; van den Berg JA; Monbaliu J; Thoolen BJ; Beems RB; van Kreijl CF
Toxicol Pathol; 2004; 32(2):192-201. PubMed ID: 15200157
[TBL] [Abstract][Full Text] [Related]
2. Xpa and Xpa/p53+/- knockout mice: overview of available data.
van Kreijl CF; McAnulty PA; Beems RB; Vynckier A; van Steeg H; Fransson-Steen R; Alden CL; Forster R; van der Laan JW; Vandenberghe J
Toxicol Pathol; 2001; 29 Suppl():117-27. PubMed ID: 11695547
[TBL] [Abstract][Full Text] [Related]
3. Phenacetin acts as a weak genotoxic compound preferentially in the kidney of DNA repair deficient Xpa mice.
Luijten M; Speksnijder EN; van Alphen N; Westerman A; Heisterkamp SH; van Benthem J; van Kreijl CF; Beems RB; van Steeg H
Mutat Res; 2006 Apr; 596(1-2):143-50. PubMed ID: 16464479
[TBL] [Abstract][Full Text] [Related]
4. Deregulation of cancer-related pathways in primary hepatocytes derived from DNA repair-deficient Xpa-/-p53+/- mice upon exposure to benzo[a]pyrene.
van Kesteren PC; Zwart PE; Pennings JL; Gottschalk WH; Kleinjans JC; van Delft JH; van Steeg H; Luijten M
Toxicol Sci; 2011 Sep; 123(1):123-32. PubMed ID: 21715664
[TBL] [Abstract][Full Text] [Related]
5. p53 heterozygosity results in an increased 2-acetylaminofluorene-induced urinary bladder but not liver tumor response in DNA repair-deficient Xpa mice.
Hoogervorst EM; van Oostrom CT; Beems RB; van Benthem J; Gielis S; Vermeulen JP; Wester PW; Vos JG; de Vries A; van Steeg H
Cancer Res; 2004 Aug; 64(15):5118-26. PubMed ID: 15289314
[TBL] [Abstract][Full Text] [Related]
6. DNA repair-deficient Xpa and Xpa/p53+/- knock-out mice: nature of the models.
van Steeg H; de Vries A; van Oostrom CTh ; van Benthem J; Beems RB; van Kreijl CF
Toxicol Pathol; 2001; 29 Suppl():109-16. PubMed ID: 11695546
[TBL] [Abstract][Full Text] [Related]
7. Effect of heterozygous loss of p53 on benzo[a]pyrene-induced mutations and tumors in DNA repair-deficient XPA mice.
van Oostrom CT; Boeve M; van Den Berg J; de Vries A; Dollé ME; Beems RB; van Kreijl CF; Vijg J; van Steeg H
Environ Mol Mutagen; 1999; 34(2-3):124-30. PubMed ID: 10529736
[TBL] [Abstract][Full Text] [Related]
8. Finding transcriptomics biomarkers for in vivo identification of (non-)genotoxic carcinogens using wild-type and Xpa/p53 mutant mouse models.
Jonker MJ; Bruning O; van Iterson M; Schaap MM; van der Hoeven TV; Vrieling H; Beems RB; de Vries A; van Steeg H; Breit TM; Luijten M
Carcinogenesis; 2009 Oct; 30(10):1805-12. PubMed ID: 19696161
[TBL] [Abstract][Full Text] [Related]
9. Use of DNA repair-deficient XPA transgenic mice in short-term carcinogenicity testing.
van Steeg H; Klein H; Beems RB; van Kreijl CF
Toxicol Pathol; 1998; 26(6):742-9. PubMed ID: 9864090
[TBL] [Abstract][Full Text] [Related]
10. The in vivo rodent test systems for assessment of carcinogenic potential.
van der Laan JW; Spindler P
Regul Toxicol Pharmacol; 2002 Feb; 35(1):122-5. PubMed ID: 11846641
[TBL] [Abstract][Full Text] [Related]
11. Detection of genotoxic and non-genotoxic carcinogens in Xpc(-/-)p53(+/-) mice.
Melis JP; Speksnijder EN; Kuiper RV; Salvatori DC; Schaap MM; Maas S; Robinson J; Verhoef A; van Benthem J; Luijten M; van Steeg H
Toxicol Appl Pharmacol; 2013 Jan; 266(2):289-97. PubMed ID: 23153559
[TBL] [Abstract][Full Text] [Related]
12. P53+/- hemizygous knockout mouse: overview of available data.
Storer RD; French JE; Haseman J; Hajian G; LeGrand EK; Long GG; Mixson LA; Ochoa R; Sagartz JE; Soper KA
Toxicol Pathol; 2001; 29 Suppl():30-50. PubMed ID: 11695560
[TBL] [Abstract][Full Text] [Related]
13. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
Gaylor DW
Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
[TBL] [Abstract][Full Text] [Related]
14. Neonatal mouse model: review of methods and results.
McClain RM; Keller D; Casciano D; Fu P; MacDonald J; Popp J; Sagartz J
Toxicol Pathol; 2001; 29 Suppl():128-37. PubMed ID: 11695548
[TBL] [Abstract][Full Text] [Related]
15. Mouse models for xeroderma pigmentosum group A and group C show divergent cancer phenotypes.
Melis JP; Wijnhoven SW; Beems RB; Roodbergen M; van den Berg J; Moon H; Friedberg E; van der Horst GT; Hoeijmakers JH; Vijg J; van Steeg H
Cancer Res; 2008 Mar; 68(5):1347-53. PubMed ID: 18316597
[TBL] [Abstract][Full Text] [Related]
16. Assessment of carcinogenicity of di(2-ethylhexyl)phthalate in a short-term assay using Xpa-/- and Xpa-/-/p53+/- mice.
Mortensen A; Bertram M; Aarup V; Sørensen IK
Toxicol Pathol; 2002; 30(2):188-99. PubMed ID: 11950162
[TBL] [Abstract][Full Text] [Related]
17. Tg.AC genetically altered mouse: assay working group overview of available data.
Eastin WC; Mennear JH; Tennant RW; Stoll RE; Branstetter DG; Bucher JR; McCullough B; Binder RL; Spalding JW; Mahler JF
Toxicol Pathol; 2001; 29 Suppl():60-80. PubMed ID: 11695563
[TBL] [Abstract][Full Text] [Related]
18. Diethylstilbestrol (DES): carcinogenic potential in Xpa-/-, Xpa-/- / p53+/-, and wild-type mice during 9 months' dietary exposure.
McAnulty PA; Skydsgaard M
Toxicol Pathol; 2005; 33(5):609-20. PubMed ID: 16178126
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after dermal application--part II.
Torrey CE; Wall HG; Campbell JA; Kwanyuen P; Hoivik DJ; Miller RT; Allen JS; Jayo MJ; Selinger K; Santostefano MJ
Int J Toxicol; 2005; 24(5):327-39. PubMed ID: 16257852
[TBL] [Abstract][Full Text] [Related]
20. Studies evaluating the utility of N-methyl-N-nitrosourea as a positive control in carcinogenicity studies in the p53+/- mouse.
Hoivik DJ; Allen JS; Wall HG; Nold JB; Miller RT; Santostefano MJ
Int J Toxicol; 2005; 24(5):349-56. PubMed ID: 16257854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]